Gonorrhea Vaccine: Could Existing Shots Offer Protection?
- Meningococcal B (MenB) vaccines coudl perhaps reduce the risk of gonorrhea, according to recent studies.
- Gonorrhea is the second most prevalent bacterial STI in the United States.In 2023, more than 600,000 cases were diagnosed.
- The rise of antibiotic-resistant strains of gonorrhea is a growing concern.
Recent studies show promise: meningococcal B vaccines may reduce teh risk of gonorrhea. Health officials are taking action, offering this potential preventative measure to high-risk groups in England. As gonorrhea cases rise,and with increasing antibiotic resistance,the possibility of this secondary_keyword offers a vital strategy. Research indicates the 4CMenB vaccine could provide up to 41% effectiveness, paving the way for further investigations. News Directory 3 is following this important health advancement – it’s critical for public health. Discover what’s next in the fight against this common STI.
Meningococcal Vaccines Show Promise in Gonorrhea Prevention
Updated May 26, 2025
Meningococcal B (MenB) vaccines coudl perhaps reduce the risk of gonorrhea, according to recent studies. Public health officials in England are now offering the vaccine to individuals at higher risk of contracting the sexually transmitted infection.
Gonorrhea is the second most prevalent bacterial STI in the United States.In 2023, more than 600,000 cases were diagnosed. The Centers for Disease Control and Prevention (CDC) estimates the actual number of annual cases to be closer to 1.6 million, as many infections are asymptomatic and go unreported.
The rise of antibiotic-resistant strains of gonorrhea is a growing concern. The bacteria has developed resistance to multiple classes of antibiotics since the 1940s, leaving cephalosporins as the only consistently effective treatment. This increasing resistance underscores the importance of effective prevention strategies.
Existing prevention methods include condoms, which prevent the exchange of bodily fluids, and Doxy PEP, an antibiotic taken after unprotected sex. Doxy PEP has demonstrated effectiveness of approximately 50% against gonorrhea and 80% against chlamydia and syphilis.
While there is no specific vaccine for gonorrhea, caused by Neisseria gonorrhoeae, scientists have been investigating whether vaccines for meningococcal meningitis, caused by the related bacterium Neisseria meningitidis, might offer cross-protection. Recent research suggests that they do.
Reviews of multiple studies by researchers in Hungary and Greece indicate that individuals who received the 4CMenB vaccine had a lower incidence of gonorrhea compared to unvaccinated individuals or those who received other meningococcal vaccines.
The 4CMenB vaccine contains outer membrane vesicles (OMV), which mimic the exterior of bacteria and stimulate an immune response without causing disease. This component may be key to the vaccine’s potential effectiveness against gonorrhea.
The Hungarian researchers’ analysis of seven studies, six focusing on the 4CMenB vaccine, revealed a pooled vaccine effectiveness of 38% against gonorrhea infection. When considering only the 4CMenB vaccine studies, the effectiveness rose slightly to 41%.
Similarly, the Greek researchers’ analysis of nine studies, eight on the 4CMenB vaccine, showed a pooled vaccine effectiveness of 30% against gonorrhea. They concluded that while randomized clinical trials are needed, their findings highlight the potential of OMV-based vaccines in gonorrhea prevention.
What’s next
Further research, including randomized clinical trials, is necessary to fully determine the effectiveness of MenB vaccines in preventing gonorrhea and to inform public health strategies.